Live Blog: Galderma Pharmaceuticals Product Theater— Soolantra (ivermectin) Cream, 1% for Rosacea
In this live blog from the Annual Summer SDPA Conference in Las Vegas, James Q. Del Rosso, MD, presented a product theater from Galderma Pharmaceuticals on Soolantra (ivermectin) Cream, 1% for Rosacea. Here are some of the highlights.
Dr. James Q. Del Rosso presented on a new and innovative treatment for rosacea called Soolantra (ivermectin) Cream, 1%. Galderma Pharmaceuticals provided sponsorship for this lecture.
Individuals with rosacea report some burning and physical discomfort, but most often, their chief concern is the psychosocial impact of their condition. “We don’t know— when we are talking to a patient in a quick office visit— how the rosacea is effecting them in life,” Dr. Del Rosso reflected. “If you can get [their condition] under control, the quality of their life is going to improve.”
Polls show that up to 14.4 million rosacea sufferers do not seek treatment. And of the 1.6 million people who do seek treatment, many feel that their current treatment regimen is not working. In fact, only 2 in 10 rosacea patients feel that their well-being has changed for the better. Medical providers want to both advocate for treatment and offer one that works. Soolantra is a new option for those positive results.
Dr. Del Rosso calls Soolantra, “a well-designed cream for rosacea-prone skin.” He continues, “Patients with rosacea, if they have inflammation, they lose water through their skin and they tend to be more sensitive to a variety of things. Soolantra Cream has a vehicle that was consciously formulated to not aggravate the skin.” Ivermectin is shown to be both an antiparisitic (treating any demodex in the area) and anti-inflammatory (reducing lesion swelling).
The efficacy and safety of Soolantra is supported by clinical data. In a 2014 randomized, double-blind, vehicle controlled pivotal study, patients treated with Soolantra saw a 64% reduction in lesions. Patients with vehicle treatment saw a 41% reduction. One Soolantra patient in the study started with 63 lesions. This count was reduced to 2 lesions by the end of the study. A clinical study for safety provided evidence that Soolantra is a very tolerable treatment with a lower incidence of related adverse events with Soolantra when compared the vehicle.
For patients with rosacea, daily use of Soolantra (ivermectin) Cream, 1% may provide relief to their physical discomfort but more importantly, it may allow our patients to regain self-confidence and reestablish their emotional well-being.